Roll-forward of TOI Activity (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2025 |
Feb. 28, 2025 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Dec. 31, 2024 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| R&D Expenses Incurred | $ 2,077,116 | $ 2,590,489 | $ 4,200,841 | $ 5,122,376 | ||||||||
| TOI Collaboration Agreement | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Amount Billed/ Submitted for Reimbursement | 1,091,385 | $ 1,544,253 | $ 1,522,770 | $ 1,467,935 | 1,168,022 | $ 1,727,386 | $ 5,886,113 | |||||
| Amount Reimbursed/ Received | (1,544,253) | (1,522,770) | (1,213,226) | (1,422,731) | (1,337,604) | (990,979) | (4,964,540) | |||||
| R&D Expenses Incurred | 1,318,212 | 1,247,806 | 1,752,591 | 1,657,091 | 1,682,980 | 1,969,270 | 7,061,932 | |||||
| Collaboration Credits | (1,336,263) | (1,233,224) | (1,755,950) | (1,658,248) | (1,685,917) | (1,966,123) | (7,066,238) | |||||
| Variance (foreign exchange timing) | 18,051 | (14,582) | 3,359 | 1,117 | 2,937 | (3,147) | 4,266 | |||||
| Adjustment to Deferred Collaboration Credits | 75,731 | (55,395) | 238,264 | 10,015 | 163,277 | 251,304 | $ 20,336 | $ 414,581 | 662,860 | |||
| Adjustment to Accrued Expenses | $ 151,096 | $ 7,456 | $ (8,443) | 179,141 | $ 351,681 | (9,420) | $ 512,959 | |||||
| Phase 3 | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Amount Billed/ Submitted for Reimbursement | $ 254,709 | $ 389,782 | $ 1,213,226 | $ 1,337,604 | ||||||||
| Q4 2024 Collaboration Receivable | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Amount Reimbursed/ Received | $ (601,197) | |||||||||||